William Blair & Company
GBT

William Blair & Company’s Global Blood Therapeutics, Inc. GBT Stock Holding History

William Blair & Company’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,872
Closed -$991K – 1921
2020
Q4 		$991K Buy
22,872
+10,542
+85% +$520K ﹤0.01% 854
2020
Q3 		$680K Sell
12,330
-113
-0.9% -$7.18K ﹤0.01% 885
2020
Q2 		$786K Sell
12,443
-1,083
-8% -$74.3K ﹤0.01% 795
2020
Q1 		$691K Sell
13,526
-8,378
-38% -$561K ﹤0.01% 776
2019
Q4 		$1.74M Sell
21,904
-29,591
-57% -$1.75M 0.01% 642
2019
Q3 		$2.5M Buy
51,495
+7,154
+16% +$373K 0.01% 527
2019
Q2 		$2.33M Buy
44,341
+6,043
+16% +$347K 0.01% 537
2019
Q1 		$2.03M Buy
38,298
+31,738
+484% +$1.56M 0.01% 561
2018
Q4 		$269K Sell
6,560
-2,590
-28% -$97K ﹤0.01% 1120
2018
Q3 		$348K Buy
9,150
+500
+6% +$22.1K ﹤0.01% 1074
2018
Q2 		$391K Sell
8,650
-3,285
-28% -$150K ﹤0.01% 1030
2018
Q1 		$576K Buy
+11,935
New +$666K ﹤0.01% 877

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company's GBT Position: Q1 2021 in Review

William Blair & Company sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 22,872 shares — an estimated $991K sold.

William Blair & Company first reported a position in GBT in Q1 2018 and held it in 12 quarters. The position peaked at $2.5M in Q3 2019. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

  • William Blair & Company reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • William Blair & Company sold 22,872 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $991K.
  • William Blair & Company first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 12 quarters.
  • William Blair & Company's Global Blood Therapeutics, Inc. position peaked at $2.5M in Q3 2019.
  • 214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on William Blair & Company's 13F filing for Q1 2021, filed 13 May 2021.